SCHEMBL1269481

SCHEMBL1269481

Cc1cc(NS(=O)(=O)c2ccc(C(F)(F)F)cc2Cl)nnc1Sc1ccc(S(=O)(=O)N2CCCCC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.43
▸ L3MBTL1 Q9Y468 3/20 0.43
▸ ATM Q13315 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CCKBR P32239 1/20 0.42
▸ LMNA P02545 5/20 0.40
▸ GLA P06280 1/20 0.40
▸ GAA P10253 3/20 0.40
▸ PIK3C3 Q8NEB9 1/20 0.39
▸ HCRTR1 O43613 1/20 0.38
▸ HCRTR2 O43614 1/20 0.38
▸ MCL1 Q07820 4/20 0.38
▸ HTT P42858 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ POLB P06746 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1269787 0.86 ALDH1A1 (0.40) ALDH1A1L3MBTL1TSHRMEN1KMT2A
SCHEMBL1269747 0.86 ALDH1A1 (0.42) ALDH1A1L3MBTL1ATMTSHRMEN1
SCHEMBL1269703 0.83 CCKBR (0.44) ALDH1A1L3MBTL1ATMTSHRMEN1
SCHEMBL1269584 0.83 ALDH1A1 (0.43) ALDH1A1L3MBTL1ATMTSHRMEN1
SCHEMBL1269926 0.83 ALDH1A1 (0.46) ALDH1A1L3MBTL1ATMTSHRMEN1
SCHEMBL12900226 0.82 GAA (0.41) ALDH1A1L3MBTL1MEN1KMT2ALMNA
SCHEMBL12900217 0.80 GAA (0.42) ALDH1A1L3MBTL1LMNAGLAGAA
SCHEMBL1268625 0.80 ALDH1A1 (0.39) ALDH1A1L3MBTL1ATMTSHRMEN1
SCHEMBL1268542 0.79 ALDH1A1 (0.42) ALDH1A1L3MBTL1ATMTSHRMEN1
SCHEMBL1269559 0.78 ALDH1A1 (0.38) ALDH1A1L3MBTL1ATMTSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
US-7893077-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2011-02-22 — — US disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
EP-1786782-B1 BISARYL-SULFONAMIDES AMGEN INC (US) 2010-03-31 — — EP disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-20090221584-A1 Bisaryl-sulfonamides AMGEN INC. 2009-09-03 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
US-7544702-B2 Bisaryl-sulfonamides AMGEN INC. (US) 2009-06-09 — — US disclosed
EP-1786782-A2 BISARYL-SULFONAMIDES Amgen Inc. (US) 2007-05-23 — — EP disclosed
US-20060084802-A1 Bisaryl-sulfonamides AMGEN INC. 2006-04-20 — — US disclosed
WO-2006020830-A2 BISARYL-SULFONAMIDES AMGEN INC. (US) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221584-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG ALDH1A1 2237/4885L3MBTL1 3486/4885ATM 3485/4885
US-20060084802-A1 Bisaryl-sulfonamides PPARD, PPARA, PPARG ALDH1A1 2237/4885L3MBTL1 3486/4885ATM 3485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback